Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Symlin And How To Market On Montel Williams

Executive Summary

During the PhRMA annual meeting March 18, Amylin CEO Ginger Graham took talk show host Montel William's advice to be proactive in working with him: she volunteered to come on his program, "The Montel Williams Show," to talk about the diabetes agent Symlin (pramlintide), which was approved by FDA two days earlier. In the following exchange, transcribed by "The Pink Sheet," Graham and Williams discuss ways to present a balanced message about a new drug. As of March 22, Amylin said it had not yet made any firm plans with Williams to do a program.

You may also be interested in...

PR Advice To PhRMA: More Communication And Communicate With Moore

The pharmaceutical industry should cooperate with documentary film maker Michael Moore, talk show host Larry King recommended during the Pharmaceutical Research & Manufacturers of America annual meeting March 18 in Washington, D.C

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts